Overall survival of driver mutation-negative non-small cell lung cancer patients with COPD under chemotherapy compared to non-COPD non-small cell lung cancer patients

Figures & data

Table 1 Baseline clinical characteristics of the study patients

	Non-COPD (n=105) (n, %)	COPD (n=92) (n, %)	p-value
Sex
Male	70 (66.7)	79 (85.9)	0.002
Age (years)	64.7±10.4	69.5±9.4	0.001
Stage			0.235
IIIB	21 (20.0)	25 (27.2)
IV	84 (80.0)	67 (72.8)
BMI (kg/m^2)	22.9±3.6	23.1±3.2	0.747
Smoking			0.009
Never-smoker	37 (35.2)	17 (18.5)
Ever-smoker	68 (64.8)	75 (81.5)
ECOG			0.515
0–1	85 (81.0)	71 (77.2)
2–3	20 (19.0)	21 (22.8)
Pathology			0.001
Squamous	24 (22.9)	46 (50.0)
Non-squamous	81 (77.1)	46 (50.0)
FEV1 (L)	2.18±0.91	1.76±0.61	<0.001
FEV1 (% predicted)	87.93±21.70	71.55±21.97	<0.001
FVC (L)	2.78±0.91	3.08±1.04	0.118
FVC (% predicted)	82.10±20.54	86.84±21.82	0.029
FEV1/FVC (% predicted)	77.39±6.11	57.65±9.19	<0.001
DLCO (abs)	16.43±15.87	16.65±16.22	0.926
DLCO (%)	76.19±20.99	73.38±20.89	0.400

Abbreviations: Abs, absolute; BMI, body mass index; COPD, chronic obstructive pulmonary disease; DLCO, diffusing capacity of the lung for carbon monoxide; ECOG, Eastern Cooperative Oncology Group; FEV₁, forced expiratory volume in 1 s; FVC, forced vital capacity.

Table 2 Univariate analysis of clinical variables affecting overall survival of the patients

Parameter	Hazard ratio	95% confidence interval	Median survival (months)	p-value
Sex				0.371
Male	1.188	0.819–1.710	8.7
Female	1		14.3
ECOG				<0.001
0–1	1		11.5
2–3	2.337	1.587–3.441	5.4
Age (years)				0.023
≤70	1		11.6
>70	1.461	1.058–2.018	7.3
Stage				0.757
IIIB	1.060	0.732–1.535	8.4
IV	1	1	10.7
BMI (kg/m^2)				0.623
<23	1.083	0.787–1.492	9.2
≥23	1		10.8
COPD				0.037
None	1		11.5
Yes	1.402	1.020–1.927	9.2
Smoking				0.398
None	1		13.9
Yes	1.161	0.821–1.640	8.7
Histology				0.004
Squamous	1.641	1.173–2.295	7.8
Non-squamous	1		12.5

Abbreviations: BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; COPD, chronic obstructive pulmonary disease.

Figure 1 Overall survival of non-small cell lung cancer patients: COPD group versus non-COPD group.

Abbreviation: COPD, chronic obstructive pulmonary disease.

Table 3 Univariate and multivariate analyses of prognostic factors for overall survival in smokers (n=154)

Parameter	Univariate analysis			Multivariate analysis
	Hazard ratio	95% confidence interval	p-value	Hazard ratio	95% confidence interval	p-value
Presence of COPD			0.019			0.006
COPD	1.585	1.080–2.327		1.726	1.170–2.54
Non-COPD	1			1
Male	1.443	0.876–2.379	0.150
ECOG			0.001			<0.001
0–1	1			1
2–3	2.303	1.433–3.702		2.602	1.603–4.221
Squamous	1.567	1.067–2.302	0.022	1.316	0.881–1.964	0.180
Age (years)			0.009			0.144
≤70	1			1
>70	1.667	1.134–2.448		1.355	0.902–2.036
Stage			0.543
IIIB	1
IV	0.877	0.576–1.337
BMI (kg/m^2)			0.929
<23	1.017	0.696–1.488
≥23	1

Abbreviations: COPD, chronic obstructive pulmonary disease; ECOG, Eastern Cooperative Oncology Group; BMI, body mass index; FEV₁, forced expiratory volume in 1 s; FVC, forced vital capacity.

Figure 2 Overall survival of non-small cell lung cancer patients according to the presence of COPD in smoker patients.

Abbreviation: COPD, chronic obstructive pulmonary disease.

Table 4 Univariate and multivariate analyses of prognostic factors for overall survival in stage IV NSCLC patients (n=151)

Parameter	Univariate analysis			Multivariate analysis
	Hazard ratio	95% confidence interval	p-value	Hazard ratio	95% confidence interval	p-value
Presence of COPD			0.025			0.039
COPD	1.530	1.054–2.222		1.479	1.020–2.145
Non-COPD	1			1
Male	1.103	0.741–1.641	0.630
ECOG			<0.001			<0.001
0–1	1			1
2–3	2.335	1.507–3.617		2.271	1.466–3.519
Squamous	1.365	0.916–2.035	0.126
Age (years)			0.012			0.189
≤70	1			1
>70	1.616	1.113–2.348		1.306	0.877–1.944
Smoker	1.080	0.735–1.588	0.694
BMI (kg/m^2)			0.737
<23	0.939	0.649–1.358
≥23	1

Abbreviations: COPD, chronic obstructive pulmonary disease; ECOG, Eastern Cooperative Oncology Group; BMI, body mass index; NSCLC, non-small cell lung cancer.

Figure 3 Overall survival of non-small cell lung cancer patients according to the presence of COPD in stage IV non-small cell lung cancer patients.

Abbreviation: COPD, chronic obstructive pulmonary disease.